Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2025-12-31 @ 4:19 AM
Study NCT ID:
NCT04895761
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-10
First Post:
2021-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Sponsor:
Providence Health & Services
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-10
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-17
First Submit QC Date:
None
Study First Post Date:
2021-05-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-06
Last Update Post Date:
2025-03-10
Last Update Post Date Type:
ACTUAL